SEC EDGARJUN 101 min read$ISRG

LOEB GARY sold $170K of ISRG

LOEB GARY (EVP & Chief Legal and Complian) sold 400 shares of INTUITIVE SURGICAL INC (ISRG) at $424.14 ($0.17M total) on 2026-06-10 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · LOEB GARY

Published Jun 10, 2026, 9:51 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 10, 2026, 9:53 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$ISRG

Neutral

medium confidence

Mentioned

$ISRG

Relevance

3/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ISRGNeutralLow

Why it matters

The disclosure adds a fresh datapoint on insider activity but does not include any operational, financial, or regulatory change.

Market read

A modest, pre-arranged insider sale is unlikely to drive a sustained repricing without accompanying company-specific catalysts.

What to watch

Traders may over-weight small insider sales; the key is whether there are repeated sales patterns or concurrent operational/regulatory news (not present here).

Relevance 3/10Novelty 8/10Timing: Filed 2026-06-10 (transaction dated 2026-06-10)

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Intuitive Surgical (ISRG).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ISRGNeutralMedium confidence

Context

Intuitive Surgical disclosed an open-market sale by EVP & Chief Legal and Compliance Officer Gary Loeb: 400 shares sold at $424.14 on 2026-06-10 under a 10b5-1 plan.

Expected impact

Likely minimal near-term impact; any effect would be sentiment-only and quickly absorbed.

Evidence & confidence

The filing is a Form 4 insider transaction and explicitly states a pre-arranged Rule 10b5-1 plan; the disclosed size ($169.7k) is small relative to typical ISRG market context, so it’s unlikely to change earnings or risk materially.

Market effects

Sector

No clear read-across to medical device sector fundamentals; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.

Key entities

issuer
ISRG
Intuitive Surgical, Inc., the subject of the Form 4 insider transaction.
insider
Gary Loeb
EVP & Chief Legal and Compliance Officer who sold 400 shares on 2026-06-10 under a Rule 10b5-1 plan.

Read at source ← All news

SEP 4

$ISRGMedAI 8/10

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

aol.com2 min

AUG 31

$ISRGMedAI 8/10

New da Vinci Surgical Robot Secures Marketing Approval: Entering Olympus’ Core Dominant Surgical Market

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

eu.36kr.com3 min

AUG 25

$NKELow

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

yahoo.com2 min

AUG 24

$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

yahoo.com3 min

AUG 23

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.